Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study — Ian Chau (2018) | RDL Network
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
Article 2018 en
Authors
IC
Ian Chau
JP
Joon Oh Park
BR
Baek‐Yeol Ryoo
Abstract
1 min read
Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.
Andrew X. Zhu, Richard S. Finn, Yoon‐Koo Kang, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C. Widau, Chunxiao Wang, Paolo Abada, Masatoshi Kudo
Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Éric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min‐Hua Jen, N. Drove Ubreva, Ryan C. Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X. Zhu
Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun‐Ming Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu
Masatoshi Kudo, Finn R.S., Manabu Morimoto, Rau K.-M., Masafumi Ikeda, Yen C.-J., Galle P.R., Llovet J.M., Bruno Daniele, Lim H.Y., M. W., Reigetsu Yoshikawa, Kenichi Nakamura, K. Liang, C. Wang, Paolo Abada, Widau R.C., Xiaoli Zhu
Discussion(0)
No comments yet. Be the first to comment.